Korean J Pediatr.  2008 May;51(5):457-461. 10.3345/kjp.2008.51.5.457.

Update on treatment in acute stage of Kawasaki disease

• Han JW

• KMID: 2280449
• DOI: http://doi.org/10.3345/kjp.2008.51.5.457

Abstract

Kawasaki disease (KD) was first described by Dr. Tomisaku Kawasaki in his 1975 study, published in Pediatrics. Its pathogenesis is still not clearly understood. Early diagnosis and treatment are very important to preventing concomitant coronary artery complications. Most KD patients respond well to the standard treatment of aspirin and intravenous immunoglobulin; however, some of them are refractory to the standard treatment, and so adjuvant therapies with corticosteroids and anti-tumor necrosis factor-alpha (TNF-alpha) antibody are necessary. In this article, the author reviews and summarizes the most recent literature on the treatment of refractory KD.

Keyword

Refractory Kawasaki disease; Adjuvant therapy

MeSH Terms

Adrenal Cortex Hormones
Aspirin
Coronary Vessels
Early Diagnosis
Humans
Mucocutaneous Lymph Node Syndrome
Necrosis
Pediatrics
Adrenal Cortex Hormones
Aspirin